

#### Japara Healthcare Limited

PO Box 16082, Collins Street West VIC 8007 Q1 Building Level 4, 1 Southbank Boulevard, Southbank VIC 3006 Telephone 03 9649 2100 Facsimile 03 9649 2129 www.japarahealthcare.com.au ABN 54 168 631 052

16 May 2016

## Appendix 3B - New Issue Announcement re Dividend Reinvestment Plan

As previously advised to the ASX, the Board of Japara Healthcare Limited (ASX: JHC) ("the Company") has determined to pay a fully franked 2016 interim dividend of 5.75 cents per share on 16 May 2016 to eligible shareholders on the Company's register as at the Record Date of 8 April 2016.

Attached is an Appendix 3B for the issue of 642,865 ordinary shares under the Company's Dividend Reinvestment Plan ("DRP") for this dividend.

The shares will be issued at \$2.89 per share. This price has been determined using the arithmetic average of the daily volume weighted average market price for the Company's ordinary shares sold on the ASX (subject to certain exclusions) during the period from 13 April 2016 to 27 April 2016 inclusive. No discount has been applied when determining the issue price.

For further information please contact:

Bruce Paterson
Company Secretary
Japara Healthcare Limited

T: (03) 9649 2100

E: bruce.paterson@japara.com.au

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

ABN		
4 168	6 631 052	
Ve (t	he entity) give ASX the followin	g information.
	1 - All issues ust complete the relevant sections (attack	h sheets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	642,865
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	N/A

Name of entity

Japara Healthcare Limited

o4/o3/2013 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$2.89 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued under the Company's Dividend Reinvestment Plan for the 2016 interim dividend.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	N/A
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

<i>7</i> -		3.T / A	
6e	Number of *securities issued with security holder approval	N/A	
	under rule 7.3, or another		
	specific security holder approval		
	(specify date of meeting)		
6f	Number of *securities issued	N/A	
	under an exception in rule 7.2		
6g	If *securities issued under rule	N/A	
	7.1A, was issue price at least 75%		
	of 15 day VWAP as calculated under rule 7.1A.3? Include the		
	+issue date and both values.		
	Include the source of the VWAP		
	calculation.		
6h	If *securities were issued under	N/A	
	rule 7.1A for non-cash		
	consideration, state date on which valuation of		
	consideration was released to		
	ASX Market Announcements		
6i	Calculate the entity's remaining	N/A	
OI .	issue capacity under rule 7.1 and	14/11	
	rule 7.1A – complete Annexure 1		
	and release to ASX Market Announcements		
7	<sup>+</sup> Issue dates	16 May 2016	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in		
	rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with		
	the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all	263,689,457	Ordinary shares
	+securities quoted on ASX		
	(including the *securities in section 2 if applicable)		
	Tr		

04/03/2013 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

	•		
		Number	+Class
9	Number and +class of all	684,075	Performance rights –
	+securities not quoted on ASX		2015/16 LTI
	(including the *securities in		arrangements
	section 2 if applicable)		
10	Dividend policy (in the case of a	Unchanged	
	trust, distribution policy) on the		
	increased capital (interests)		
Dt	2 Due vote issue		
Part	2 - Pro rata issue		
		77/4	
11	Is security holder approval	N/A	
	required?		
12	Is the issue renounceable or non-	N/A	
	renounceable?	11/11	
13	Ratio in which the *securities	N/A	
	will be offered		
14	*Class of *securities to which the	N/A	
	offer relates		
	+D 1 1 1.	NI/A	
15	<sup>+</sup> Record date to determine entitlements	N/A	
	entitiements		
16	Will holdings on different	N/A	
10	registers (or subregisters) be	14/11	
	aggregated for calculating		
	entitlements?		
17	Policy for deciding entitlements	N/A	
	in relation to fractions		
18	Names of countries in which the	N/A	
10	entity has security holders who	IN/A	
	will not be sent new offer		
	documents		
	Note: Security holders must be told how their		
	entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
10	Closing data for	NI / A	
19	Closing date for receipt of acceptances or renunciations	N/A	
	acceptances of renunctations		

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 4 04/03/2013

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

04/03/2013 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B	
New issue an	nouncement

32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	N/A
	t 3 - Quotation of securitied only complete this section if you are	
34	Type of *securities (tick one)	
(a)	*Securities described in Pa	art 1
(b)	*	e end of the escrowed period, partly paid securities that become fully paid, when restriction ends, securities issued on expiry or conversion of convertible
	tional securities forming a ne	
35	If the +securities are +equi	ty securities, the names of the 20 largest holders of the I the number and percentage of additional <sup>+</sup> securities
36	1 1	ity securities, a distribution schedule of the additional number of holders in the categories
37	A copy of any trust deed for	or the additional <sup>+</sup> securities
Entit	ies that have ticked box 34(b)	
38	Number of *securities for whice *quotation is sought	ch

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	rvamber	Ciuos

### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

04/03/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

- There is no reason why those \*securities should not be granted \*quotation.
- An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 16 May 2016

Company Secretary

Print name: Bruce Paterson

== == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.